Esmya® is an oral Selective Progesterone Receptor Modulator (SPRM) characterized by a tissue‑specific partial progesterone antagonist effect1.
Esmya® directly acts on the endometrium, the fibroids and the pituitary gland1.
Endometrium | Histological changes lead to reduced uterine bleeding |
Fibroids | Blockade of progesterone receptors, inhibition of cell proliferation and induction of apoptosis reduces their size |
Pituitary gland | Ovulation is inhibited, LH and FSH secretion is partially suppressed, and mid-follicular oestrogen levels are maintained |
FSH, follicle-stimulating hormone; LH, luteinising hormone